Ziltivekimab ZEUS Trial: Why the IL-6 Heart Drug Failed
- 11 views
- 0 likes
- 0 comments
- All languages combined

Sign in and earn +30 points by reading this
Read to the end, wait a few seconds, then tap the claim button below.
In short
As of 13 November 2026, the ZEUS trial, published in the New England Journal of Medicine, found that Novo Nordisk's IL-6 antibody ziltivekimab lowered inflammation markers sharply but did not reduce heart attacks, strokes or cardiovascular deaths versus placebo in 6,376 high-risk patients [1][2]. Serious infections were more common [1].
Key takeaways
- ZEUS tested monthly ziltivekimab injections against placebo in adults with atherosclerotic cardiovascular disease, chronic kidney disease and raised hsCRP, an inflammation marker [1].
- Major cardiovascular events occurred in 17.6% on ziltivekimab and 17.7% on placebo (hazard ratio 0.99; 95% CI 0.88 to 1.11) over a median 33 months [1].
- The drug cut free IL-6 by 76 percentage points and hsCRP by 64 percentage points compared with placebo at 24 months [1].
- Serious infections occurred in 20.4% versus 17.9% [1].
- Lead investigator Paul Ridker suggested the patients' disease may have been too advanced to modify [2].
- Novo Nordisk booked a DKK 4.6 billion impairment on ziltivekimab; after a monitoring committee's recommendation it closed the HERMES heart failure trial, while ATHENA was completing as planned [4].
On this page 11 sections
- What did the ZEUS trial find?
- What is ziltivekimab?
- Who was in the ZEUS trial?
- What did the secondary results and safety data show?
- Why did ziltivekimab not reduce heart events?
- What does ZEUS mean for patients with high hsCRP?
- What happens next for ziltivekimab?
- Common mistakes
- Frequently asked questions
- Glossary
- Sources
What did the ZEUS trial find?
Ziltivekimab did not lower the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke: events occurred in 561 patients (17.6%) on the drug and 565 (17.7%) on placebo, a hazard ratio of 0.99 (P = 0.84) [1].
- Inflammation fell: at 24 months, the difference versus placebo was −76 percentage points for free IL-6 and −64 percentage points for hsCRP [1].
- Components: cardiovascular death 11.1% versus 11.2%, non-fatal heart attack 4.5% versus 4.6%, and non-fatal stroke 3.6% versus 3.9%, according to the trial's AHA presentation slides [5].
- Follow-up: median 33 months [1].
- Serious adverse events: 54.6% versus 54.8% [1].
- Serious infections: 20.4% versus 17.9% [1].
- Death from any cause: no difference, Novo Nordisk said [3].
The results were presented at the American Heart Association's Scientific Sessions on 7 November 2026 and published in the New England Journal of Medicine [1][2]. Novo Nordisk had already announced the headline result on 31 July 2026 [3].
The table below sets out the main figures.
What is ziltivekimab?
Ziltivekimab is an investigational monoclonal antibody from Novo Nordisk that neutralises interleukin-6 (IL-6), an inflammatory signalling protein; in ZEUS it was given as a 15 mg injection under the skin once a month [1].
- The theory: the NEJM paper says IL-6 "is hypothesized to be a therapeutic target" in atherosclerotic cardiovascular disease and chronic kidney disease [1].
- Target engagement: Novo Nordisk said the drug "produced the expected biological effect" on the IL-6 pathway [3].
- Not approved: ziltivekimab is an experimental drug in phase 3 trials [3][4].
- Infection risk: Novo Nordisk said the higher rate of serious infections was "consistent with targeting IL-6 inhibition" [3].
Martin Holst Lange, Novo Nordisk's chief scientific officer, said in July that ziltivekimab "did not achieve the MACE benefit we had hoped for" but that the company's commitment to cardiovascular disease was unchanged [3].
Who was in the ZEUS trial?
ZEUS enrolled adults with established atherosclerotic cardiovascular disease, chronic kidney disease and cardiovascular inflammation, defined as hsCRP of at least 2 mg per litre [1].
- Size: 6,376 patients in the full analysis population: 3,184 on ziltivekimab and 3,192 on placebo [1]. The AHA summary gives 6,395 randomised [2].
- Sites: 757 sites in 38 countries [5].
- Age and sex: mean age 69.4 years; 27.5% were women [1].
- Design: multinational, double-blind, randomised 1:1, placebo-controlled [1].
- Adherence: the presentation slides report average adherence of 85.6%, with 1.3% lost to follow-up [5].
- Background treatment: 92.6% took lipid-lowering drugs; SGLT2 inhibitor use rose from 37.1% at the start to 52.1% at completion, and GLP-1 receptor agonist use from 11.4% to 18.6% [5].
- Baseline markers: median hsCRP 4.5 mg/L, median IL-6 4.9 pg/mL, median LDL cholesterol 71 to 72 mg/dL (by group), mean eGFR 44.5 mL/min/1.73 m² [5].
- Other conditions: about two-thirds had diabetes, over 92% hypertension and around 42% heart failure [5].
- Funding: Novo Nordisk [1].
The trial was registered as NCT05021835 [1].
What did the secondary results and safety data show?
None of the four confirmatory secondary endpoints showed a clear difference between ziltivekimab and placebo, while serious infections, cellulitis and venous blood clots were more frequent on the drug, according to the trial's AHA presentation slides [5].
- Expanded MACE (adding hospitalisation for unstable angina needing urgent revascularisation): 18.4% versus 18.5%, hazard ratio 0.99 [5].
- Heart failure hospitalisations, urgent heart failure visits or cardiovascular death: 17.1% versus 17.6%, mean ratio 0.94 (0.83 to 1.07) [5].
- Composite kidney endpoint (a sustained fall in eGFR of at least 40% from baseline, death from kidney failure or cardiovascular causes, or kidney failure): 20.2% versus 19.3%, hazard ratio 1.05 (0.94 to 1.17) [5].
- All-cause mortality: 16.9% versus 17.0%, hazard ratio 0.99 [5].
The safety slide marks these events as statistically significant (Fisher's exact test, p < 0.05) [5]:
- Serious adverse events of infection: 20.4% versus 17.9%.
- Cellulitis: 2.9% versus 1.0%.
- Infection as the primary cause of hospitalisation: 17.1% versus 14.8%.
- Serious venous thromboembolism (blood clots in veins): 1.6% versus 0.6%.
Serious haemorrhage was 5.1% versus 4.0%, deaths due to infection 3.2% versus 2.5%, and opportunistic infections 2.7% versus 2.2%; the slide does not mark these as statistically significant [5]. Malignant neoplasms were 6.4% versus 6.7% [5].
Subgroup results by sex, age, diabetes, kidney function, body weight, baseline hsCRP and IL-6 showed no subgroup with a clear benefit; the lowest hazard ratio, in people with a body mass index under 25, was 0.76 (95% CI 0.57 to 1.00) [5]. Subgroup analyses are exploratory.
Why did ziltivekimab not reduce heart events?
No definitive answer exists, but lead investigator Paul Ridker hypothesised that "the severe underlying disease in these participants may have been nonmodifiable", adding: "The horse may already have been out of the barn" [2].
Ridker, of Harvard Medical School and Brigham and Women's Hospital, said cardiovascular inflammation remains highly prevalent and a "mechanistically compelling" target beyond lowering cholesterol [2].
- Earlier success with other targets: the AHA notes that large trials inhibiting interleukin-1 or using colchicine have reduced cardiovascular events in select patients [2].
- CANTOS (2017): canakinumab, an antibody against interleukin-1β, cut recurrent cardiovascular events: in 10,061 people with a previous heart attack, the 150 mg dose every 3 months gave a hazard ratio of 0.85 (95% CI 0.74 to 0.98) [6].
- CANTOS infection signal: canakinumab was linked to more fatal infections, and all-cause mortality did not differ [6].
- Upstream targets: Ridker pointed to opportunities for IL-6 inhibition in earlier disease and for targeting the NLRP3 inflammasome [2].
The ZEUS slides compare the two trials' populations directly [5]:
- Mean age: 61 years in CANTOS versus 69 in ZEUS.
- Diabetes: 40% versus 66%.
- Heart failure: 22% versus 42%.
- High or very high kidney risk (KDIGO class): 11.4% versus 71.8%.
- Kidney function (eGFR): 80 versus 45 mL/min/1.73 m².
- Major cardiovascular events per 100 person-years: 4.5 versus 6.8; deaths from any cause 3.0 versus 6.2.
The slides also cite the CANTOS, LoDoCo2 and COLCOT trials as evidence that anti-inflammatory therapy can reduce cardiovascular events, and frame the open question as "what drug in which patient group?" [5]. A further slide notes that genetic evidence linking IL-6 to heart disease does not prove that blocking it reverses disease: "Genetic Causality is Not Therapeutic Reversibility" [5].
Lowering a biomarker did not translate into fewer events here. For why AI chatbots can get findings like this wrong, see AI Hallucinations Explained: Why Chatbots Make Things Up and How to Get Accurate Answers.
What does ZEUS mean for patients with high hsCRP?
Ridker said people with elevated hsCRP "need strong recommendations for preventive care", noting that diet, exercise and stopping smoking all lower hsCRP [2].
He listed statins, colchicine, canakinumab and GLP-1 receptor agonists as therapies that "positively impact patients with residual inflammatory risk" [5]. The list includes canakinumab, which was tested in CANTOS; the presentation does not say it is approved for this use [5]. These are his views as presented, not recommendations from ZEUS itself [2][5].
- ZEUS does not show harm to the heart: cardiovascular death and heart attack rates were nearly identical in both groups [1][5].
- Infections: the excess of serious infections is a safety consideration for IL-6 blockade [1][3].
- No approved IL-6 heart drug: ziltivekimab remains experimental [3][4].
This is not medical advice. Decisions about your own treatment belong with a qualified clinician who knows your history.
What happens next for ziltivekimab?
Novo Nordisk's financial report for the first nine months of 2026, published on 4 November, says the ZEUS and HERMES trials did not meet their primary endpoints, and the company took a DKK 4.6 billion non-cash impairment related to ziltivekimab [4].
- Heart failure trials: after a data monitoring committee recommended ending HERMES and ATHENA in heart failure with preserved ejection fraction, Novo stopped study treatment and closed HERMES; ATHENA was completing as planned [4].
- Timing: results from HERMES and ATHENA are expected in the first half of 2027 [4].
- After heart attack: the ARTEMIS phase 3 trial in people after an acute heart attack is listed for results [4]. In July, Novo said ARTEMIS was expected to read out in the first half of 2027 [3].
The AHA session also reported that pelacarsen, a lipoprotein(a)-lowering drug, did not reduce major cardiovascular events in the Lp(a) HORIZON trial [2]. What AI tools can and cannot do in health care is covered in AI in Healthcare: What It Can Do Today, Where It Fails and How It Is Regulated.
Common mistakes
Assuming lower inflammation means fewer heart attacks
Fix: hsCRP fell 64 points, yet events did not change [1].
Saying inflammation does not matter for the heart
Fix: Ridker says it remains a compelling target; IL-1 and colchicine trials succeeded [2][5].
Thinking ziltivekimab is available
Overlooking infections
Fix: Serious infections were 20.4% vs 17.9% [1].
Treating ZEUS as the end of the programme
Fix: ARTEMIS and heart failure trial results are still due [4].
Frequently asked questions
What did the ZEUS trial find?
Heart events were 17.6% on ziltivekimab vs 17.7% on placebo; no reduction [1].
Who was in the ZEUS trial?
6,376 adults with atherosclerosis, kidney disease and raised hsCRP [1].
What did the secondary results and safety data show?
No secondary endpoint showed a clear difference; cellulitis and venous blood clots were more common on the drug [5].
Why did ziltivekimab not reduce heart events?
Ridker suggests the disease was too advanced to modify; this is a hypothesis [2].
What does ZEUS mean for patients with high hsCRP?
Ridker urges strong preventive care; ZEUS itself offers no new treatment [2].
Glossary
- Interleukin-6 (IL-6)
- A signalling protein that drives inflammation.
- hsCRP
- High-sensitivity C-reactive protein, a blood marker of inflammation.
- MACE
- Major adverse cardiovascular events: here CV death, heart attack or stroke.
- Monoclonal antibody
- A lab-made antibody designed to bind one specific target.
- Atherosclerosis
- Build-up of fatty plaque in artery walls.
- Impairment
- An accounting write-down of an asset's value.
Sources
- Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease New England Journal of Medicine · 2026-11-07
- Lessons from landmark trials American Heart Association Scientific Sessions · 2026-11-07
- Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation Novo Nordisk (SEC filing) · 2026-07-31
- Financial report for the period 1 January 2026 to 30 September 2026 Novo Nordisk (SEC filing) · 2026-11-04
- Interleukin-6 Inhibition for Atherosclerotic Disease: Primary Report of the Ziltivekimab Cardiovascular Outcomes Study (ZEUS), AHA 2026 slides Novo Nordisk Science Hub · 2026-11-07
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS) New England Journal of Medicine · 2017-08-27
Comments
Top comments